Wells Fargo & Company Catalyst Pharmaceuticals, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 37,420 shares of CPRX stock, worth $654,101. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,420
Previous 28,343
32.03%
Holding current value
$654,101
Previous $476,000
25.21%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CPRX
# of Institutions
279Shares Held
95.6MCall Options Held
40.6KPut Options Held
67.2K-
Black Rock Inc. New York, NY17.7MShares$310 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$160 Million3.01% of portfolio
-
State Street Corp Boston, MA8.15MShares$143 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.98MShares$140 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.74MShares$47.9 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $1.8B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...